Therapy News and Research

RSS

Myriad to present new clinical data on Prolaris® at the AUA 2015 annual meeting

Myriad Genetics, Inc. announced it will present three studies that demonstrate the value of the Prolaris test for physicians and their patients at the 2015 American Urological Association (AUA) Annual Meeting being held May 15 to 19 in New Orleans, La...

7 May 2015

Study analyzes outcomes of brain metastases patients following stereotactic radiosurgery

Winner of the Leksell Radiosurgery Award, Deborah C. Marshall, recently presented her research, Survival Patterns of Patients with Cerebral Metastases after Multiple Rounds of Stereotactic Radiosurgery (SRS), at the 2015 American Association of Neurological Surgeons Annual Scientific Meeting.

7 May 2015

Quantitative phosphoproteomic approach to identify targeted cancer therapy

Winner of the Louise Eisenhardt Traveling Scholarship Award, Teresa Purzner, MD, presented her research, Quantitative Phosphoproteomics for Targeted Cancer Therapy.

7 May 2015

MSI completes patient recruitment for STRADA Phase 2 trial for treatment of major depressive disorder

MSI Methylation Sciences, Inc., a pharmaceutical company developing a once-daily oral, small molecule therapy for adjunctive treatment of major depressive disorder (MDD), announced the completion of patient recruitment for its HORIZON Phase 2 Study.

7 May 2015

New Griffith research program aims to reduce negative impact of anxiety

Combatting the negative impact of anxiety using cognitive behavioural therapy is the aim of a new research program run by Griffith University, in the face of this significant issue.

7 May 2015

Stanford University professor named recipient of 2015 ECOG-ACRIN Young Investigator Award

Heather Wakelee, MD, is the recipient of the 2015 ECOG-ACRIN Young Investigator Award, the ECOG-ACRIN Cancer Research Group announced today. Dr. Wakelee is associate professor of medicine in the Division of Oncology at the Stanford University School of Medicine in Stanford, Calif.

7 May 2015

Scientists uncover new pharmaceutical strategy for treating melanoma

Scientists looking to better understand the mechanisms behind the origin and spread of melanoma tumors have uncovered a possible role for a decades-old antibacterial agent in treating these aggressive and increasingly common cancers.

6 May 2015

UTHealth professor awarded $1 million grant from Stryker Neurovascular for stroke research

A $1 million grant for stroke research has been awarded from Stryker Neurovascular to Amrou Sarraj, M.D., assistant professor of neurology at The University of Texas Health Science Center at Houston.

From Stryker 6 May 2015

Elekta striving to build radiation therapy infrastructures and save lives of cancer patients in Africa

In Africa, cancer kills more people than HIV/AIDS, malaria and tuberculosis combined. Approximately 40 percent of cancer cases can be prevented and 40 percent can be cured with the right treatment. Together with Elekta, ministries of health in almost a dozen African nations are working to build up their radiation therapy infrastructures and save lives.

From Elekta 6 May 2015

Symbiomix closes $41 million Series A financing and reports positive results from SYM-1219 Phase 2 trial

Symbiomix Therapeutics today announced multiple milestones, including the closing of the third and final tranche of a $41 million Series A financing and positive results from a multi-center, randomized Phase 2 trial testing a single oral dose of SYM-1219 for the treatment of bacterial vaginosis (BV).

6 May 2015

AbbVie's venetoclax granted FDA Breakthrough Therapy Designation for CLL patients with 17p deletion

AbbVie today announced its investigational medicine venetoclax, an inhibitor of the B-cell lymphoma-2 (BCL-2) protein that is being developed in partnership with Genentech and Roche, has been granted Breakthrough Therapy Designation by the FDA for the treatment of chronic lymphocytic leukemia (CLL) in previously treated (relapsed/refractory) patients with the 17p deletion genetic mutation.

6 May 2015

Partners congratulate researchers on forming new biotechnology company

The Children's Hospital of Eastern Ontario, The Ottawa Hospital, the University of Ottawa and McMaster University congratulate its researchers on forming Turnstone Biologics Inc., a biotechnology company focused on developing new treatments for cancer that harness the patient's own immune system.

6 May 2015

Weston Park Hospital offers two cutting-edge treatments for rare cancer tumours, prostate cancer

TWO cutting-edge cancer treatments using targeted radioactive therapy injections to destroy cancer cells are now being offered to patients with rare neuroendocrine tumours and patients with prostate cancer at Weston Park Hospital.

6 May 2015

Scientists identify mechanism that explains how some stem cells get new identity

Scientists at the University of Copenhagen have identified one mechanism that explains how some stem cells choose to become a given cell type: the cells combine specific sets of proteins at precise positions along the DNA. When these particular groups of proteins are combined, the gates are opened so that certain groups of genes can now be used, giving the cells a new identity.

6 May 2015

ViiV Healthcare initiates Phase III trial to evaluate dolutegravir and rilpivirine in HIV patients

ViiV Healthcare today announced the start of a Phase III clinical trial programme to evaluate the safety and efficacy of dolutegravir (Tivicay) and rilpivirine (Edurant) as maintenance therapy for adult patients with HIV.

6 May 2015

Automated PoCyton cytometer effective for counting cancer cells

Biological and medical scientists have been using flow cytometry to count cancer cells for the past 40 years. But the large instruments are expensive and can only be operated by trained personnel. By contrast the PoCyton cytometer developed by Fraunhofer researchers is cheap to produce, no bigger than a shoebox, and automated.

6 May 2015

Acacia Pharma reports positive results from APD403 Phase 2 study in CINV

Acacia Pharma Ltd, a specialty pharmaceutical company developing supportive care products for post-surgical and cancer patients in the US and international markets, announces positive results from its Phase 2 study of APD403 in the prevention of chemotherapy-induced nausea & vomiting (CINV).

6 May 2015

E-learning can provide efficient approach to training psychotherapists in new evidence-based treatments

Employing online training programs to teach psychotherapists how to use newer evidence-based treatments can be as successful as in-person instruction, according to a new RAND Corporation study.

6 May 2015

Johns Hopkins researchers develop new strategies to treat depression in children, adolescents

A multidisciplinary team of Johns Hopkins researchers has developed two new strategies to treat depression in young people using the selective serotonin reuptake inhibitor (SSRI) class of medications. These strategies, published May 5 in the journal Translational Psychiatry, incorporate a new understanding of how to mitigate the risk of suicide while on SSRI treatment.

6 May 2015

Researchers study early response of cells to ischemia

A group of researchers from the Lomonosov Moscow State University in collaboration with their Irish colleagues from the University College Cork has studied the early response of cells to ischemia, which is a restriction in blood supply to tissues causing the death of the cell.

6 May 2015

Therapy News and Research

Myriad to present new clinical data on Prolaris® at the AUA 2015 annual meeting

Study analyzes outcomes of brain metastases patients following stereotactic radiosurgery

Quantitative phosphoproteomic approach to identify targeted cancer therapy

MSI completes patient recruitment for STRADA Phase 2 trial for treatment of major depressive disorder

New Griffith research program aims to reduce negative impact of anxiety

Stanford University professor named recipient of 2015 ECOG-ACRIN Young Investigator Award

Scientists uncover new pharmaceutical strategy for treating melanoma

UTHealth professor awarded $1 million grant from Stryker Neurovascular for stroke research

Elekta striving to build radiation therapy infrastructures and save lives of cancer patients in Africa

Symbiomix closes $41 million Series A financing and reports positive results from SYM-1219 Phase 2 trial

AbbVie's venetoclax granted FDA Breakthrough Therapy Designation for CLL patients with 17p deletion

Partners congratulate researchers on forming new biotechnology company

Weston Park Hospital offers two cutting-edge treatments for rare cancer tumours, prostate cancer

Scientists identify mechanism that explains how some stem cells get new identity

ViiV Healthcare initiates Phase III trial to evaluate dolutegravir and rilpivirine in HIV patients

Automated PoCyton cytometer effective for counting cancer cells

Acacia Pharma reports positive results from APD403 Phase 2 study in CINV

E-learning can provide efficient approach to training psychotherapists in new evidence-based treatments

Johns Hopkins researchers develop new strategies to treat depression in children, adolescents

Researchers study early response of cells to ischemia

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News